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Superior vena cava syndrome (SVCS) is characterized by a spectrum of clinical ﬁndings
that  result from the occlusion of the superior vena cava (SVC), usually caused by extra-
caval compression of the SVC by either a bronchogenic tumor or an enlarged mediastinal
lymph node. Most efforts at treatment for SVCS are palliative, and long-term survival for
malignancy-related SVCS is very low. Therefore, radiotherapy treatment is usually delivered
with palliative intent utilizing hypofractionated regimens. The use of high dose per fraction
may result in more rapid and more durable responses to treatment. Similarly, the high dose
per  fraction utilized in stereotactic body radiotherapy (SBRT) has been proven highly efﬁ-uperior vena cava syndrome
BRT
VCS
cacious in treating early stage non-small cell lung cancer (NSCLC). Here we  report the ﬁrst
reported case of a patient with SVCS from NSCLC successfully treated with SBRT to alleviate
SVCS.
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Therefore, radiotherapy treatment is usually delivered with.  Background
uperior vena cava syndrome (SVCS) is characterized by a
pectrum of clinical ﬁndings that result from the occlusion
f the superior vena cava (SVC). The typical manifestations
enerally include edema and distention of the veins of the
pper chest wall, upper extremities, neck, face and head. As
ymptoms progress patients may experience dyspnea, cough,
tridor, headache or neurologic dysfunction related to cerebral
dema.
Most cases of SVCS are caused by extracaval compres-
ion of the SVC by either a bronchogenic tumor or an
nlarged mediastinal lymph node. Speciﬁcally, right paratra-
heal lymph nodes are the most common nodal site involved.
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Radiotherapy or chemotherapy is most commonly utilized
to treat the offending lesion with the goal of relieving com-
pression and restoring normal, physiologic ﬂow through the
SVC. The choice of which of these modalities to employ is
largely dependent upon the histology of the obstructing lesion.
Patients with chemosensitive tumors such as small cell lung
cancers (SCLC) are typically treated with chemotherapy, while
less sensitive tumors such as non-small cell lung cancers
(NSCLC) are typically treated with radiotherapy.
Most efforts at treatment for SVCS are palliative, and
long-term survival for malignancy-related SVCS is very low.ancer Center, 234 Goodman Street, ML0757, Cincinnati, OH 45267,
palliative intent utilizing hypofractionated regimens. The use
of high dose per fraction may result in more  rapid and more
durable responses to treatment. Similarly, the high dose per
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Anterior chest wall collateral vessels.
Fig. 2 – Coronal reconstruction of a CT of the thorax with
contrast revealing occlusion of the superior vena cava
secondary to a right paratracheal lymph node. Collateral
administered every other day. Dose was prescribed to the 95%
isodose line covering the PTV (Fig. 3). Following his second
treatment he was noted to have an appreciable response tofraction utilized in stereotactic body radiotherapy (SBRT) has
been proven highly efﬁcacious in treating early stage NSCLC.
Here we  report the case of a patient with SVCS from NSCLC
treated with SBRT in an attempt to alleviate his SVCS and
simultaneously offer deﬁnitive treatment for his underlying
malignancy.
2.  Case  report
A previously healthy 82-year-old white male presented to the
hospital with the complaint of a 3–4 day history of swelling of
the face, neck, and left arm. The patient denied any shortness
of breath, stridor, pain, or neurologic changes and otherwise
felt well. Despite his symptoms he was able to carry on with
his normal activities of daily living. He did however admit
to a chronic, productive cough, and also endorsed a smoking
history of approximately 70-pack-years.
At the time of presentation, physical exam was signiﬁcant
for edema of the bilateral upper extremities and face associ-
ated with well-formed collateral vessels on the anterior chest
wall (Fig. 1).
Due to a high clinical suspicion for SVCS, a thoracic CT with
contrast was performed, revealing a 2.5 cm mediastinal mass
consistent with a pathologically enlarged right paratracheal
lymph node completely obstructing the SVC (Fig. 2). Well-
formed collateral vessels bypassing the obstructed portion of
the SVC were noted as well.
The patient was clinically stable, therefore complete work-
up and staging was performed. Endobronchial ultrasound
guided biopsy of the offending right paratracheal lymph node
revealed squamous cell carcinoma. PET/CT revealed increased
uptake within the obstructing lymph node with no other evi-
dence of disease throughout.Given the patient’s small overall volume of disease, small
offending lesion size, and evidence of possible improved out-
comes with large dose per fraction, SBRT was chosen as thevessels are apparent proximal to the obstructing lesion.
optimal treatment modality. The intent of treatment was to
both palliate his SVCS and deﬁnitively treat his NSCLC.
The patient underwent respiratory gated CT simulation
with images acquired during passive breathing, inhalation
and exhalation. To aid with immobilization a custom vac-
uum bag was conformed to the patients head, neck, thorax,
abdomen and pelvis. The offending lesion was then delin-
eated on each phase of the planning CT scan as gross tumor
volume (GTV). All three identiﬁed GTVs were then fused to
generate an internal target volume (ITV). Given that the lesion
did not move with respiration, and was located wholly within
the mediastinum, an expansion of 3 mm around the ITV was
used to construct the planning target volume (PTV). He was
then treated with three-dimensional conformal radiotherapy
using 6 MV photons from a Varian Trilogy linear accelerator
(Varian, Palo Alto, CA). Twelve coplanar beams were used to
deliver a total dose of 50 Gy in ﬁve fractions of 10 Gy each,Fig. 3 – Axial dose distribution of treatment plan.
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herapy. His facial and upper extremity edema had resolved
ompletely by the completion of treatment.
The patient reported no acute side effects from his radia-
ion treatment. At the time of last follow-up he was 3 months
ut from completion of therapy. At the time he reported
ormal breathing without dyspnea or chest pain. His upper
xtremity edema had resolved although the collaterals evi-
ent on his anterior chest wall remained.
.  Discussion
t is reported that up to 90% of SVCS cases are due to
alignancy.1 Of those cases, approximately 80% are secondary
o a primary bronchogenic carcinoma. SVCS is actually the
rst presenting symptom in 10% of patients with SCLC and in
.7% of patients with NSCLC.2 The obstruction in malignancy-
elated SVCS is usually caused by local extension of a right
pper lobe tumor or, more  commonly, enlarging mediastinal
denopathy with the right paratracheal node being most fre-
uently involved.3
The prognosis is generally poor for malignancy-related
VCS, with studies demonstrating average survival time after
iagnosis of SVCS due to NSCLC of 5–12 months.4,5 In NSCLC,
he response to therapy for SVCS has not been as favorable as
hen related to SCLC. In a systematic review, external beam
adiotherapy (EBRT) offered complete resolution of SVCS in
8% of patients with SCLC and in 63% of patients with NSCLC.1
SCLC has been demonstrated to be somewhat more  respon-
ive to radiation therapy than chemotherapy, with complete
elief obtained in 63% and 58% of patients, respectively.1
The rate of response of the symptoms of SVCS to EBRT
s variable and highly dependent on the tumor histology. In
eneral, there is usually some symptomatic improvement evi-
ent within 72 h after beginning EBRT, but some cases have
een documented wherein relief was not provided for up to
 weeks. Multiple studies have reported that approximately
0% of patients will exhibit no response to EBRT.1,6,7 However,
igh initial EBRT doses may result in a more  rapid and more
urable response to therapy. In addition, survival appears to
e prolonged in those who  respond within 30 days of initiating
herapy.4
SBRT is a relatively new development with excellent out-
omes reported for early stage lung cancer. Utilizing this
echnique to deliver high doses per fraction has resulted in
ery high rates of local control.8 Given the small volume and
ocality of disease, this patient offered a unique clinical sce-
ario to achieve both relief of SVCS and potentially deﬁnitive
reatment. For those patients with centrally located tumors,
xcessive toxicity has been reported with very large doses per
raction.9 This excessive toxicity prompted an ongoing radi-
tion therapy oncology group (RTOG) dose escalation trial for
9therapy 1 8 ( 2 0 1 3 ) 179–181 181
patients with centrally located tumors. Therefore, the patient
was electively treated with the starting dose as per the cur-
rent dose escalation protocol. Thus far he has had resolution
of his SVCS and represents the ﬁrst documented case in the
literature of utilizing SBRT for the treatment of SVCS.
4.  Summary
Superior vena cava syndrome (SVCS) is a clinical syndrome
that affects many  patients during their course of cancer treat-
ment, and radiotherapy is a major modality of therapy for
many  of these patients. Higher radiation doses per fraction
have been associated with improved outcomes. SBRT may be
ideal for select patients who present with SVCS.
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